These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7823605)

  • 1. Surrogate endpoint biomarker assays in phase II chemoprevention clinical trials.
    Lipkin M; Bhandari M; Hakissian M; Croll W; Wong G
    J Cell Biochem Suppl; 1994; 19():47-54. PubMed ID: 7823605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of recommendations for colonic biomarker studies of candidate chemopreventive compounds in phase II clinical trials.
    Lipkin M
    J Cell Biochem Suppl; 1994; 19():94-8. PubMed ID: 7823612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early development of cancer chemoprevention clinical trials: studies of dietary calcium as a chemopreventive agent for human subjects.
    Lipkin M
    Eur J Cancer Prev; 2002 Aug; 11 Suppl 2():S65-70. PubMed ID: 12570337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention of colon carcinogenesis by the natural product of a simple phenolic compound protocatechuic acid: suppressing effects on tumor development and biomarkers expression of colon tumorigenesis.
    Tanaka T; Kojima T; Suzui M; Mori H
    Cancer Res; 1993 Sep; 53(17):3908-13. PubMed ID: 8358716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat.
    Wargovich MJ; Chen CD; Jimenez A; Steele VE; Velasco M; Stephens LC; Price R; Gray K; Kelloff GJ
    Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):355-60. PubMed ID: 9162301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large bowel adenomas: markers of risk and endpoints.
    Baron JA
    J Cell Biochem Suppl; 1996; 25():142-8. PubMed ID: 9027611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of chemoprevention of dietary Agaricus blazei against rat colonic aberrant crypt foci.
    Ziliotto L; Barbisan LF; Rodrigues MA
    Hum Exp Toxicol; 2008 Jun; 27(6):505-11. PubMed ID: 18784204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability of rectal epithelial kinetic patterns as an intermediate biomarker of colon cancer.
    Anti M; Marra G; Percesepe A; Armelao F; Gasbarrini G
    J Cell Biochem Suppl; 1994; 19():68-75. PubMed ID: 7823608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
    Meyskens FL; Gerner EW
    Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cohorts with familial disposition for colon cancers in chemoprevention trials.
    Burt RW
    J Cell Biochem Suppl; 1996; 25():131-5. PubMed ID: 9027609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer.
    Tao L; Wang W; Kramer PM; Lubet RA; Steele VE; Pereira MA
    Mol Carcinog; 2004 Feb; 39(2):79-84. PubMed ID: 14750212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprevention of large bowel carcinogenesis; the role of control of cell proliferation and significance of beta-catenin-accumulated crypts as a new biomarker.
    Mori H; Yamada Y; Hirose Y; Kuno T; Katayama M; Sakata K; Yoshida K; Sugie S; Hara A; Yoshimi N
    Eur J Cancer Prev; 2002 Aug; 11 Suppl 2():S71-5. PubMed ID: 12570338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New rodent models for studies of chemopreventive agents.
    Lipkin M
    J Cell Biochem Suppl; 1997; 28-29():144-7. PubMed ID: 9589360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin.
    Wali RK; Khare S; Tretiakova M; Cohen G; Nguyen L; Hart J; Wang J; Wen M; Ramaswamy A; Joseph L; Sitrin M; Brasitus T; Bissonnette M
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1653-62. PubMed ID: 12496057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of aberrant crypt foci by dietary fat and caloric restriction: the effects of delayed intervention.
    Lasko CM; Bird RP
    Cancer Epidemiol Biomarkers Prev; 1995; 4(1):49-55. PubMed ID: 7894324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.